Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Jays Group on a rights issue
Mandate

Vinge advises Jays Group on a rights issue

May 19, 2019 Capital Markets and Public M&A

The board of directors of Jays Group AB (publ) has resolved pursuant to authorization granted at an annual general meeting to perform a new issue of shares amounting to approximately MSEK 41 subject to pre-emption rights for the company’s existing shareholders.

Pursuant to subscription undertakings and guarantee obligations, the new issue of shares is secured to approximately MSEK 36.9, corresponding to 90% of the total proceeds of the new issue of shares. The offer is performed in order to further strengthen the company’s trademark and product portfolio and strengthen the balance sheet prior to future acquisition financing. The prospectus is planned to be published on 24 May and the subscription period commences on 27 May.

Vinge’s team consists of responsible partner Anders Strid together with Frida Bergqvist (project manager), Jenny Sandlund, Victor Ericsson (tax) and Camilla Andersson (company assistant).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025